| Literature DB >> 35932019 |
Shiqiang Xiong1, Qiang Chen1, Xu Chen1, Jun Hou1, Yingzhong Chen1, Yu Long1, Siqi Yang1, Lingyao Qi1, Hong Su1, Wenchao Huang1, Hanxiong Liu1, Zhen Zhang2, Lin Cai3.
Abstract
BACKGROUND: The Global Registry of Acute Coronary Events (GRACE) score derived from clinical parameters at the time of hospital discharge is a powerful predictor of long-term mortality and reinfarction after acute coronary syndrome (ACS). The triglyceride glucose (TyG) index, which is a simple and reliable surrogate marker of insulin resistance, has been demonstrated to be an independent predictor of long-term adverse major adverse cardiac events, irrespective of diabetes mellitus. We investigate whether the addition of the TyG index improves the predictive ability of the GRACE score after percutaneous coronary intervention (PCI) in ACS patients regardless of diabetes mellitus.Entities:
Keywords: Acute coronary syndrome; Fasting blood glucose; GRACE score; Insulin resistance; Major adverse cardiac events; Percutaneous coronary intervention; Prognosis; Residual SYNTAX score; The triglyceride-glucose index
Mesh:
Substances:
Year: 2022 PMID: 35932019 PMCID: PMC9356419 DOI: 10.1186/s12933-022-01582-w
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 8.949
Baseline characteristics of the patients stratified by the TyG index tertiles
| Variable | T1(n = 332) | T2 (n = 327) | T3 (n = 327) | P value |
|---|---|---|---|---|
|
| ||||
| Age, years | 68.10 ± 11.89 | 66.65 ± 10.95 | 65.07 ± 11.24 | 0.003 |
| SBP, mmHg | 131.28 ± 19.81 | 133.17 ± 22.69 | 132.25 ± 21.66 | 0.525 |
| h, bpm | 76.15 ± 14.41 | 78.15 ± 14.95 | 78.66 ± 14.96 | 0.071 |
| Serum creatinine, umol/L | 77.60 (65.55, 90.75) | 78.10 (66.80, 92.70) | 73.20 (61.10, 90.20) | 0.046 |
| CHF, n (%) | 125 (37.7) | 128 (39.1) | 142 (43.4) | 0.292 |
| Previous MI, n (%) | 15 (4.5) | 21 (6.4) | 17 (5.2) | 0.548 |
| ST-segment depression, n (%) | 129 (38.9) | 124 (37.9) | 155 (47.4) | 0.025 |
| Elevated cardiac enzymes/markers, n (%) | 210 (63.3) | 221 (67.6) | 232 (70.9) | 0.108 |
|
| 110.61 ± 31.99 | 109.54 ± 29.91 | 109.30 ± 32.31 | 0.851 |
|
| 8.28 ± 0.29 | 8.96 ± 1.73 | 9.79 ± 0.47 | <0.001 |
| Female, n (%) | 72 (21.7) | 83 (25.4) | 124 (37.9) | <0.001 |
| BMI, kg/m2 | 23.58 ± 2.89 | 24.61 ± 2.78 | 24.77 ± 2.78 | <0.001 |
| Smoking, n (%) | 181 (54.5) | 187 (57.2) | 173 (52.9) | 0.539 |
| Previous PCI, n (%) | 30 (9.0) | 29 (8.9) | 24 (7.3) | 0.689 |
| COPD, n (%) | 22 (6.6) | 20 (6.1) | 13 (4.0) | 0.291 |
| Hypertension, n (%) | 208 (62.7) | 217 (66.4) | 214 (65.4) | 0.582 |
| Diabetes mellitus, n (%) | 49 (14.8) | 105 (32.1) | 189 (57.8) | <0.001 |
| AF, n (%) | 27 (8.1) | 20 (6.1) | 19 (5.8) | 0.431 |
| Previous Stroke, n (%) | 25 (7.5) | 27 (8.3) | 23 (7.0) | 0.839 |
|
| ||||
| cTnT, pg/mL | 28.29 (10.73, 968.00) | 30.10 (11.84, 652.60) | 59.25 (13.36, 1006.60) | 0.233 |
| BNP, pg/mL | 109.85 (45.03, 301.08) | 103.50 (32.60, 287.30) | 111.60 (38.10, 324.00) | 0.337 |
| FBG (mmol/L) | 5.39 ± 1.18 | 6.41 ± 1.82 | 9.19 ± 4.03 | <0.001 |
| TG (mmol/L) | 0.97 ± 0.28 | 1.63 ± 0.44 | 2.96 ± 1.68 | <0.001 |
| TC (mmol/L) | 4.07 ± 1.07 | 4.50 ± 1.24 | 4.85 ± 1.23 | <0.001 |
| HDL-C (mmol/L) | 1.22 ± 0.33 | 1.14 ± 0.28 | 1.10 ± 0.27 | <0.001 |
| LDL-C (mmol/L) | 2.47 ± 0.81 | 2.81 ± 0.92 | 3.22 ± 2.86 | <0.001 |
| LVEF | 55.16 ± 8.81 | 55.33 ± 8.74 | 54.22 ± 9.28 | 0.231 |
|
| 0.262 | |||
| UA | 165 (49.7) | 157 (48.0) | 143 (43.7) | |
| NSTEMI | 62 (18.7) | 77 (23.5) | 82 (25.1) | |
| STEMI | 105 (31.6) | 93 (28.4) | 102 (31.2) | |
|
| ||||
| MVD, n (%) | 202 (60.8) | 228 (69.7) | 239 (73.1) | 0.002 |
| LM, n (%) | 11 (3.3) | 23 (7.0) | 20 (6.1) | 0.091 |
| Calcified lesions, n (%) | 42 (12.7) | 44 (13.5) | 50 (15.3) | 0.603 |
| Thrombosis, n (%) | 20 (60.0) | 28 (8.6) | 31 (9.5) | 0.238 |
| Long lesion, n (%) | 131 (39.5) | 153 (46.8) | 170 (52.0) | 0.005 |
| CTO, n (%) | 54 (16.3) | 82 (25.1) | 67 (20.5) | 0.020 |
| Number of stents | 1.35 ± 0.77 | 1.47 ± 0.91 | 1.56 ± 0.94 | 0.008 |
| Length of stents, mm | 35.12 ± 23.70 | 38.71 ± 27.56 | 41.51 ± 28.00 | 0.008 |
| bSS | 11.00 (7.00, 18.00) | 14.00 (8.00, 21.00) | 14.50 (8.50, 20.50) | <0.001 |
| rSS | 2.00 (0.00, 6.00) | 3.00 (0.00, 7.50) | 3 (0.00, 8.00) | 0.010 |
| ICR, n (%) | 198 (59.6) | 220 (67.3) | 236 (72.2) | 0.003 |
|
| ||||
| Aspirin, n (%) | 322 (97.0) | 320 (97.9) | 319 (97.6) | 0.770 |
| P2Y12 receptor inhibitor, n (%) | 328 (98.8) | 324 (99.1) | 322 (98.5) | 0.775 |
| Statins, n (%) | 321 (96.7) | 319 (97.6) | 319 (97.6) | 0.733 |
| β-blockers, n (%) | 218 (65.7) | 231 (70.6) | 238 (72.8) | 0.124 |
| ACEI/ARB, n (%) | 132 (39.8) | 149 (45.6) | 135 (41.3) | 0.295 |
| Diuretics, n (%) | 50 (15.1) | 50 (15.3) | 51 (15.6) | 0.982 |
| Insulin, n (%) | 4 (1.2) | 20 (6.1) | 46 (14.1) | <0.001 |
| Oral hypoglycemic agents, n (%) | 22 (6.6) | 77 (23.5) | 123 (37.6) | <0.001 |
The patients were divided into three groups in accordance with tertiles of the TyG index [T1 (TyG index ≤ 8.65), T2 (8.65 < TyG index ≤ 9.24), and T3 (TyG index > 9.24)]. GRACE score, Global Registry of Acute Coronary Events score; TyG index, the triglyceride-glucose index; BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation; SBP, systolic blood pressure; HR, heart rate; CHF, congestive heart failure; BNP, brain natriuretic peptide; FBG, fasting blood glucose; TG, triglyceride; TC, total cholesterol; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein; LVEF, left ventricular ejection fraction; UA, unstable angina; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; MVD, multivessel disease; LM, left main disease; CTO, chronic total occlusion; bSS, baseline SYNTAX score; rSS, residual SYNTAX score; ICR, incomplete revascularization; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker. Data are presented as the mean ± SD, median (IQR) or n (%)
Comparison of long-term adverse prognosis
| Variable | Total (n = 986) | T1(n = 332) | T2(n = 327) | T3(n = 327) | P value |
|---|---|---|---|---|---|
| MACEs, n (%) | 90 (9.13) | 20 (6.02) | 27 (8.26) | 43 (13.15) | 0.005 |
| All-cause death, n (%) | 66 (6.69) | 14 (4.22) | 16 (4.89) | 36 (11.01) | 0.001 |
| Cardiac death, n (%) | 40 (4.06) | 8 (2.41) | 11(3.36) | 21 (6.42) | 0.025 |
| Myocardial infarction, n (%) | 26 (2.64) | 6 (1.81) | 11 (3.36) | 9 (2.75) | 0.454 |
| Unplanned revascularization, n (%) | 99 (10.04) | 24 (7.23) | 30 (9.17) | 45 (13.76) | 0.017 |
| Stroke, n (%) | 37 (3.75) | 11 (3.31) | 15(4.59) | 11(3.36) | 0.624 |
The patients were divided into three groups in accordance with tertiles of the TyG index [T1 (TyG index ≤ 8.65), T2 (8.65 < TyG index ≤ 9.24), and T3 (TyG index > 9.24)]. MACEs indicate major adverse cardiac events, defined as a composite of all-cause death and nonfatal myocardial infarction
Fig. 1Cumulative incidence of the incidence of primary endpoint and each clinical event according to the TyG index tertiles .Kaplan-Meier curves for the incidence of MACEs (A), all-cause death (B), cardiac death (C), unplanned repeat revascularization (D), nonfatal myocardial infarction (E), and nonfatal stroke (F) among the 3 study groups based on the TyG index tertiles. TyG indicates triglyceride-glucose
Univariate and multivariate Cox regression analysis for predicting the primary endpoint
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| GRACE score | 1.0253 | 1.0182 to 1.0325 | < 0.0001 | 1.0202 | 1.0117 to 1.0288 | < 0.0001 |
| Female | 1.5832 | 1.0334 to 2.4255 | 0.0348 | 1.3103 | 0.8403 to 2.0431 | 0.2332 |
| BMI | 0.9528 | 0.8841 to 1.0268 | 0.2050 | |||
| Smoking | 0.7895 | 0.5222 to 1.1936 | 0.2623 | |||
| Previous PCI | 1.3968 | 0.7428 to 2.6268 | 0.2997 | |||
| Hypertension | 1.3202 | 0.8409 to 2.0728 | 0.2274 | |||
| Diabetes mellitus | 1.2838 | 0.8433 to 1.9544 | 0.2440 | |||
| TyG index | 1.4961 | 1.1437 to 1.9571 | 0.0033 | 1.6028 | 1.1900 to 2.1588 | 0.0019 |
| HDL-C | 0.9716 | 0.4767 to 1.9805 | 0.9368 | |||
| LDL-C | 0.9249 | 0.7572 to 1.1297 | 0.4441 | |||
| bSS | 1.0537 | 1.0324 to 1.0755 | < 0.0001 | 1.0244 | 0.9992 to 1.0502 | 0.0574 |
| ICR | 1.9863 | 1.2077 to 3.2669 | 0.0069 | 1.2399 | 0.7231 to 2.1259 | 0.4345 |
| LVEF | 0.9448 | 0.9269 to 0.9629 | < 0.0001 | 0.9773 | 0.9548 to 1.0003 | 0.0530 |
| AMI | 1.9438 | 1.2533 to 3.0148 | 0.0030 | 0.8695 | 0.5326 to 1.4196 | 0.5761 |
| β-blockers | 0.9299 | 0.5975 to 1.4473 | 0.7475 | |||
| Diuretics | 3.2982 | 2.1419 to 5.0787 | < 0.0001 | 1.5413 | 0.9234 to 2.5727 | 0.0979 |
| ACEI/ARB | 1.2600 | 0.8330 to 1.9057 | 0.2737 | |||
| Insulin | 1.4863 | 0.7696 to 2.8704 | 0.2380 | |||
The primary endpoint was defined as a composite of all-cause death and nonfatal myocardial infarction. HR, hazard ratio; CI, confidence interval; GRACE score, Global Registry of Acute Coronary Events score; the TyG index, the triglyceride-glucose index; BMI, body mass index; FBG, fasting blood glucose; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein; CTO, chronic total occlusion; ICR, incomplete revascularization; LVEF, left ventricular ejection fraction; AMI, acute myocardial infarction; bSS, baseline SYNTAX score; rSS, residual SYNTAX score; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker
Fig. 2ROC curve analysis evaluating the diagnostic performance for MACEs in ACS patients undergoing PCI. A The area under the curve (AUC) of the TyG index for predicting MACEs was 0.607 (95% CI: 0.576–0.638, P = 0.001). B The AUC of the FBG for predicting MACEs was 0.586 (95% CI: 0.554–0.617, P = 0.005). The AUC of the TG (C) for predicting MACEs was 0.563 (95% CI: 0.532–0.594, P = 0.0039). The AUC of the GRACE score (D) for predicting MACEs was 0.723 (95% CI: 0.694–0.750, P < 0.001). ROC, receiver operating characteristic; ACS, acute coronary syndrome; MACEs, major adverse cardiac events; PCI, percutaneous coronary intervention; TyG, triglyceride-glucose; FBG, fasting blood glucose; TG, triglyceride
Fig. 3Subgroups analyses of the TyG index for MACEs. HR was evaluated by 1-point increase of the TyG index. HR, hazard ratio; TyG, triglyceride-glucose; CI, confidence interval; ACS, acute coronary syndrome; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; CR, complete revascularization, defined as residual SYNTAX score = 0
Akaike’s information criteria and likelihood ratio test to determine the best fitting model for predicting MACEs
| Akaike’s information criteria | Likelihood ratio test | |||||||
|---|---|---|---|---|---|---|---|---|
| Model | AICc | δAICc | AICcWt | Cum.wt | Model | χ2 | df | P value |
| GRACE score | 1098.73 | 10.35 | 0.01 | 1.00 | GRACE score | Ref. | Ref. | Ref. |
| GRACE score + TyG index | 1088.38 | 0.00 | 0.99 | 0.99 | GRACE score + TyG index | 12.37 | 1 | <0.001 |
| GRACE score + FBG | 1100.47 | 12.09 | 0.00 | 1.00 | GRACE score + FBG | 0.27 | 1 | 0.604 |
MACEs indicates major adverse cardiac events, defined as a composite of all-cause death and nonfatal myocardial infarction. GRACE score, Global Registry of Acute Coronary Events score; TyG index, the triglyceride-glucose index; FBG, fasting blood glucose; AICc, corrected Akaike’s information criterion; δAICc, delta-AICc; AICcWt, AICc weights; Cum.wt, the cumulative weights of AIC
Evaluation the incremental prognostic value of adding the TyG index to the GRACE score to predict clinical outcomes
| C-index (95% CI) | P value | NRI (95% CI) | P value | IDI (95% CI) | P value | |
|---|---|---|---|---|---|---|
| GRACE score | 0.735 (0.682, 0.788) | < 0.01 | Ref. | Ref. | Ref. | Ref. |
| GRACE score + FBG | 0.735 (0.681, 0.789) | < 0.01 | 0.068 (-0.165,0.248)) | 0.50 | 0.001 (-0.001,0.013) | 0.39 |
| GRACE score + TyG index | 0.744 (0.688, 0.800) | < 0.01 | 0.282 (0.028, 0.426) | 0.02 | 0.019 (0.004, 0.046) | 0.01 |
| GRACE score | 0.750 (0.690, 0.810) | < 0.01 | Ref. | Ref. | Ref. | Ref. |
| GRACE score + FBG | 0.753 (0.694, 0.812) | < 0.01 | 0.085 (− 0.193, 0.203) | 0.41 | 0.002 (-0.001, 0.025) | 0.39 |
| GRACE score + TyG index | 0.765 (0.704, 0.826) | < 0.01 | 0.308 (0.017, 0.445) | 0.03 | 0.026 (0.004, 0.053) | <0.01 |
| GRACE score | 0.776 (0.708, 0.844) | <0.01 | Ref. | Ref. | Ref. | Ref. |
| GRACE score + FBG | 0.776 (0.708, 0.844) | < 0.01 | 0.079 (− 0.145, 0.241) | 0.49 | 0.000 (− 0.001, 0.019) | 0.52 |
| GRACE score + TyG index | 0.785 (0.714, 0.856) | < 0.01 | 0.336 (0.031, 0.485) | 0.01 | 0.015 (0.003, 0.047) | <0.01 |
| GRACE score | 0.655 (0.609, 0.701) | < 0.01 | Ref. | Ref. | Ref. | Ref. |
| GRACE score + FBG | 0.658 (0.612, 0.704) | < 0.01 | 0.099 (-0.067,0.231) | 0.23 | 0.002 (0.000, 0.009) | 0.20 |
| GRACE score + TyG index | 0.673 (0.626, 0.720) | < 0.01 | 0.267 (0.106, 0.418) | < 0.01 | 0.017 (0.005, 0.035) | <0.01 |
MACEs indicates major adverse cardiac events, defined as a composite of all-cause death and nonfatal myocardial infarction. GRACE score, Global Registry of Acute Coronary Events score; TyG index, the triglyceride-glucose index; MI, myocardial infarction; CI, confidence interval; NRI, net reclassification improvement; IDI, integrated discrimination improvement
Fig. 4ROC curve analysis of the model performance after adding the TyG index to the baseline GRACE score. The areas under the ROC curves were used to compare the predictive ability between the baseline GRACE score and the TyG index plus the GRACE score for MACEs (A), all-cause death (B), cardiac death (C), and all-cause death, MI, or unplanned revascularization (D). ROC, receiver operating characteristic; TyG, triglyceride-glucose; MACEs, major adverse cardiac events; MI, myocardial infarction
Fig. 5The calibration plots for adverse cardiovascular events. Calibration curves for MACEs (A), all-cause death (B), cardiac death (C), and all-cause death, MI or unplanned revascularization (D). The x-axis represents the predicted adverse cardiovascular events risk. The y-axis represents the actual adverse cardiovascular events rate. The grey line indicates a perfect prediction by an ideal model. The red solid line indicates the performance of the predicting model, of which a closer fit to the grey line suggests better prediction. MACEs, major adverse cardiac events; MI, myocardial infarction